There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Kura Oncology (NASDAQ:KURA) and Editas Medicine Inc (NASDAQ:EDIT) with bullish sentiments.
Kura Oncology (KURA)
Oppenheimer analyst Leah R. Cann maintained a Buy rating on Kura Oncology yesterday and set a price target of $35. The company’s shares closed yesterday at $21.15, close to its 52-week high of $24.03.
Cann said:
“Loss per share was $0.45, in line with our estimated loss of $0.45. The operating loss of $15.3 million was 1.3% higher than our estimated ($15.1) million, primarily due to higher than estimated SG&A. Net interest income was basically in line with our estimates. Shares outstanding were 1.4% higher than we estimated. Our revenue outlook for 2018 – 2022 is unchanged. Our estimated loss per share is unchanged in 2018, and for 2019 – 2022 all our per-share estimates are modestly decreased, primarily due to higher shares outstanding.”
According to TipRanks.com, Cann is a 5-star analyst with an average return of 21.3% and a 55.6% success rate. Cann covers the Healthcare sector, focusing on stocks such as Miragen Therapeutics Inc, CytomX Therapeutics Inc, and Crispr Therapeutics AG.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Kura Oncology with a $33 average price target, representing a 56.0% upside. In a report issued on August 1, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $31 price target.
.
See today’s analyst top recommended stocks >>
Editas Medicine Inc (EDIT)
Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Editas Medicine Inc yesterday. The company’s shares closed yesterday at $29.09.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 13.0% and a 55.6% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Voyager Therapeutics Inc.
Currently, the analyst consensus on Editas Medicine Inc is a Moderate Buy with an average price target of $39.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
